Some common IBS treatments linked to higher risk of death
Peer-Reviewed Publication
Updates every hour. Last Updated: 20-Jun-2026 20:15 ET (21-Jun-2026 00:15 GMT/UTC)
A large, long-term study led by Cedars-Sinai Health Sciences University investigators suggests that some medications commonly prescribed to treat irritable bowel syndrome (IBS)—including antidepressants—may be associated with a small but measurable increase in the risk of death.
A new study by the Hospital del Mar Research Institute and Universitat Ramon Llull establishes for the first time a direct link between good physical fitness and a reduced risk of suffering from more than thirty diseases. The study, published in Medicine & Science in Sports & Exercise, identifies a causal relationship between a greater genetic predisposition for adequate cardiorespiratory capacity and a lower risk of developing these conditions. The results suggest that increasing aerobic activity may provide protection against various cardiovascular, inflammatory, and other diseases.
A groundbreaking discovery in modernizing traditional Chinese medicine (TCM) has been achieved. A study has, for the first time, confirmed that stable, naturally occurring nanoparticles with intact bioactivity—named Pueraria lobata (GeGen) decoction-derived vesicle-like nanoparticles (GGD-PDVLNs)—exist in the decoction prepared using the traditional boiling method. Experiments have demonstrated that these nanoparticles constitute the core active component responsible for the therapeutic effects of the decoction. They function by reshaping the gut microbiota to treat ulcerative colitis, with efficacy dependent on the microbiota. This finding redefines the scientific understanding of traditional herbal decoctions and establishes a new paradigm for developing natural nanomedicines.